Sage Therapeutics, Inc. (SAGE) Is At $166.34 Formed Wedge; 11 Analysts Are Bullish Eaton plc (ETN) Last Week

Eaton Corporation plc (NYSE:ETN) Logo

Sage Therapeutics, Inc. (SAGE) formed wedge down with $158.02 target or 5.00% below today’s $166.34 share price. Sage Therapeutics, Inc. (SAGE) has $7.62 billion valuation. The stock increased 2.08% or $3.39 during the last trading session, reaching $166.34. About 64,278 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 17, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Among 31 analysts covering Eaton Corporation (NYSE:ETN), 11 have Buy rating, 2 Sell and 18 Hold. Therefore 35% are positive. Eaton Corporation had 89 analyst reports since July 31, 2015 according to SRatingsIntel. The company was upgraded on Thursday, March 1 by J.P. Morgan. The firm earned “In-Line” rating on Monday, August 7 by Evercore. The firm earned “Buy” rating on Thursday, February 4 by Citigroup. The company was maintained on Wednesday, November 1 by Jefferies. RBC Capital Markets maintained it with “Sector Perform” rating and $59 target in Monday, May 2 report. The company was maintained on Thursday, July 13 by Jefferies. Jefferies maintained it with “Hold” rating and $90.0 target in Thursday, February 1 report. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, April 3. The stock of Eaton Corporation plc (NYSE:ETN) earned “Market Perform” rating by Bernstein on Monday, November 2. The firm earned “Neutral” rating on Monday, May 2 by Buckingham Research. See Eaton Corporation plc (NYSE:ETN) latest ratings:

10/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $88.0000 Upgrade
03/04/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $88.0000 Maintain
26/03/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy Old Target: $80 Upgrade
08/03/2018 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade
01/03/2018 Broker: J.P. Morgan Rating: Hold Upgrade
01/03/2018 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Old Target: $70 Upgrade
15/02/2018 Broker: Barclays Capital Rating: Equal-Weight New Target: $90 Initiates Coverage On
05/02/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
01/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $84.0 Maintain
01/02/2018 Broker: Jefferies Rating: Hold New Target: $90.0 Maintain

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 56 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Thursday, December 7. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, September 3 by JP Morgan. Leerink Swann maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, June 20 with “Buy” rating. The firm has “Hold” rating by H.C. Wainwright given on Friday, August 4. As per Thursday, November 2, the company rating was maintained by Stifel Nicolaus. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Canaccord Genuity on Monday, November 13. Canaccord Genuity maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Monday, March 26. Canaccord Genuity has “Buy” rating and $21000 target. The firm has “Buy” rating given on Monday, October 16 by RBC Capital Markets. The rating was maintained by Canaccord Genuity on Friday, August 4 with “Buy”. The rating was maintained by SunTrust with “Buy” on Thursday, December 7.

Since December 14, 2017, it had 0 insider buys, and 3 sales for $27.36 million activity. Robichaud Albert sold $9.57 million worth of stock. Kanes Stephen had sold 44,000 shares worth $7.80 million. PAUL STEVEN M sold $10.00M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, March 6.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 EPS, down 21.71% or $0.33 from last year’s $-1.52 per share. After $-1.75 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71% negative EPS growth.

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It is positive, as 27 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Cutter Co Brokerage Incorporated holds 0.35% or 5,190 shares. Texas-based Dimensional Fund Advisors Lp has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Zeke Capital Advsrs Limited Liability Com holds 0.03% or 1,949 shares. 70,091 were reported by Element Cap Lc. Emerald Advisers Pa invested 1.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Voloridge Inv Ltd reported 53,908 shares or 0.19% of all its holdings. Cibc Asset Incorporated reported 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Franklin Resources holds 0.04% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 524,590 shares. Goldman Sachs Grp Inc reported 224,819 shares. Axa holds 0.03% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 45,120 shares. Dekabank Deutsche Girozentrale stated it has 63,450 shares. Emerald Mutual Fund Advisers Tru holds 133,323 shares. Northern Trust Corp stated it has 444,158 shares. Fred Alger Mngmt holds 6,500 shares or 0% of its portfolio. Oak Ridge Limited Liability Corporation has 2.72% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 346,597 shares.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.15, from 1 in 2017Q3. It improved, as 41 investors sold Eaton Corporation plc shares while 281 reduced holdings. 104 funds opened positions while 267 raised stakes. 331.54 million shares or 0.44% more from 330.10 million shares in 2017Q3 were reported. The Illinois-based Ubs Asset Management Americas Inc has invested 0.16% in Eaton Corporation plc (NYSE:ETN). 13,155 were reported by Orrstown Finance. 3,000 were reported by Mgmt Va. Murphy reported 0.03% in Eaton Corporation plc (NYSE:ETN). Goelzer Inv Mngmt owns 65,753 shares for 0.58% of their portfolio. Cookson Peirce & Inc invested in 0.06% or 8,525 shares. Ftb Advisors holds 0.12% of its portfolio in Eaton Corporation plc (NYSE:ETN) for 16,238 shares. West Oak Cap Limited Liability reported 0.02% in Eaton Corporation plc (NYSE:ETN). Services Corporation holds 0.16% of its portfolio in Eaton Corporation plc (NYSE:ETN) for 4,188 shares. Visionary Asset Management owns 38,311 shares or 0.84% of their US portfolio. Ls Inv Advsr Ltd invested in 18,144 shares or 0.08% of the stock. Reliant Investment Management Ltd Liability Com accumulated 2,890 shares or 0.16% of the stock. Hermes Inv Limited holds 128,169 shares or 0.15% of its portfolio. Dynamic Advsr Solutions Llc has 0.15% invested in Eaton Corporation plc (NYSE:ETN). 3,130 are held by Kelly Lawrence W & Ca.

Eaton Corporation plc operates as a power management firm worldwide. The company has market cap of $34.35 billion. The Company’s Electrical Products segment offers electrical and industrial components, residential products, single phase power quality products, emergency lighting and fire detection products, wiring devices, structural support systems, and circuit protection and lighting products. It has a 11.74 P/E ratio. The companyÂ’s Electrical Systems and Services segment provides power distribution and assemblies, three phase power quality products, hazardous duty electrical equipment, explosion-proof instrumentation, utility power distribution, power reliability equipment, and services.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart